1921
Volume 98, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Repeated oral azithromycin distribution targeted only to children has proven effective in reducing the ocular that causes trachoma. Here, we assess whether an enhanced coverage target of at least 90% of children is superior to the World Health Organization recommendation of at least 80%. Twenty-four trachoma-endemic communities in Matamèye, Niger, were randomized to a single day of azithromycin distribution aiming for at least 80% coverage or up to 4 days of treatment and > 90% coverage of children under age 12. All distributions were biannual. Children < 5 years of age and adults > 15 years were monitored for ocular infection by polymerase chain reaction every 6 months for 36 months in children and at baseline and 36 months in adults. Ocular prevalence in children decreased from 24.9% (95% confidence interval [CI] 15.9–33.8%) to 4.4% (95% CI 0.6–8.2%, < 0.001) at 36 months in the standard coverage arm and from 15.6% (95% CI 10.0–21.2%) to 3.3% (95% CI 1.0–5.5%; < 0.001) in the enhanced coverage arm. Enhanced coverage reduced ocular prevalence in children more quickly over time compared with standard ( = 0.04). There was no difference between arms at 36 months in children (2.4% lower with enhanced coverage, 95% CI 7.7–12.5%; = 0.60). No infection was detected in adults at 36 months. Increasing antibiotic coverage among children from 80% to 90% may yield only short term improvements for trachoma control programs. Targeting treatment to children alone may be sufficient for trachoma control in this setting.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.17-0501
2017-12-18
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/2/tpmd170501.html?itemId=/content/journals/10.4269/ajtmh.17-0501&mimeType=html&fmt=ahah

References

  1. Mabey DC, Solomon AW, Foster A, , 2003. Trachoma. Lancet 362: 223229. [Google Scholar]
  2. Taylor HR, Burton MJ, Haddad D, West F, Wright H, , 2014. Trachoma. Lancet 384: 21422152. [Google Scholar]
  3. World Health Organization, 2006. Trachoma Control: A Guide from Prgoramme Managers. Geneva, Switzerland: World Health Organization, 153.
  4. Harding-Esch EM, Partnership for Rapid Elimination of Trachoma (PRET) study group , 2013. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET trial in the Gambia. PLoS Negl Trop Dis 7: e2115. [Google Scholar]
  5. Lietman T, Porco T, Dawson C, Blower S, , 1999. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 5: 572576. [Google Scholar]
  6. Last AR, Burr SE, Weiss HA, Harding-Esch EM, Cassama E, Nabicassa M, Mabey DC, Holland MJ, Bailey RL, , 2014. Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naïve trachoma-hyperendemic communities of the Bijagós Archipelago, Guinea Bissau. PLoS Negl Trop Dis 8: e2900. [Google Scholar]
  7. Schemann JF, Sacko D, Malvy D, Momo G, Traore L, Bore O, Coulibaly S, Banou A, , 2002. Risk factors for trachoma in Mali. Int J Epidemiol 31: 194201. [Google Scholar]
  8. Amza A, PRET Partnership , 2012. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Negl Trop Dis 6: e1586. [Google Scholar]
  9. Grassly NC, Ward ME, Ferris S, Mabey DC, Bailey RL, , 2008. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis2: e341. [Google Scholar]
  10. Solomon AW, 2004. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 351: 19621971. [Google Scholar]
  11. House JI, 2009. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomisedtrial. Lancet 373: 11111118. [Google Scholar]
  12. Amza A, 2017. A cluster-randomized trial to assess the efficacy of targeting trachoma treatment to children. Clin Infect Dis 64: 743750. [Google Scholar]
  13. Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, Quinn T, West SK, , 2013. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trail results. JAMA Ophthalmol 131: 431436. [Google Scholar]
  14. Stare D, Harding-Esch E, Munoz B, Bailey R, Mabey D, Holland M, Gaydos C, West S, , 2011. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the partnership for rapid elimination of trachoma (PRET) in Tanzania and the Gambia. Ophthalmic Epidemiol 18: 2029. [Google Scholar]
  15. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR, , 1987. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 65: 477483. [Google Scholar]
  16. Ray KJ, Zhou Z, Cevallos V, Chin S, Enanoria W, Lui F, Lietman TM, Porco TC, , 2014. Estimating community prevalence of ocular Chlamydia trachomatis infection using pooled polymerase chain reaction testing. Ophthalmic Epidemiol 21: 8691. [Google Scholar]
  17. Holm SO, 2001. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ 79: 194200. [Google Scholar]
  18. Frick KD, Lietman TM, Osaki-Holm S, Jha H, Chaudary J, Bhatta RC, , 2001. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ 79: 201207. [Google Scholar]
  19. Chidambaram JD, 2004. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis 39: e95e97. [Google Scholar]
  20. Skalet AH, 2010. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 7: e1000377. [Google Scholar]
  21. Haug S, 2010. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51: 571574. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0501
Loading
/content/journals/10.4269/ajtmh.17-0501
Loading

Data & Media loading...

  • Received : 23 Jun 2017
  • Accepted : 23 Aug 2017
  • Published online : 18 Dec 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error